Articles tagged with Human Immunodeficiency Virus
Researchers at Vanderbilt University have isolated antibodies with a loop-like structure that binds tightly to HIV and disables it. The study suggests a new approach to rapidly induce broadly neutralizing antibodies in people who have not been exposed to HIV.
Researchers at TSRI have identified the first-ever immature HIV-neutralizing antibody, revealing a possible guide for developing an effective vaccine. The antibody, found in a Chinese patient, evolved rapidly and gained key traits within two years, contradicting previous theories.
Researchers apply global sensitivity analysis to pinpoint key HIV model parameters affecting treatment plans. By fixing non-influential inputs and minimizing parameter dimensions, they better understand HIV dynamics and develop optimal treatment strategies.
A recent study identifies multiple sexual behaviors associated with prevalent sexually transmitted infections, including HIV. Men who engaged in anal stimulation or enema use were nearly five times as likely to test positive for HIV as those who did not.
Researchers at the University of Missouri School of Medicine have identified an enzyme that may reduce the risk of cardiovascular disease caused by HIV medications. The enzyme, heme oxygenase-1 (HO-1), offers protection against endothelial cell dysfunction when used in conjunction with protease inhibitors.
The Elizabeth Glaser Pediatric AIDS Foundation has been awarded the Saving Lives at Birth: A Grand Challenge for Development Award to scale up use of the Pratt Pouch in Uganda. The model aims to reach 40,000 infants in three years with the goal of significantly reducing HIV transmission rates.
Researchers have discovered an HIV-fighting immunogen called eOD-GT8 that shows extraordinary binding affinity for naïve human B cells, outperforming previous candidates by a factor of 2100. Approximately 96% of humans harbor B cells sensitive to this immunogen, suggesting its potential as a viable HIV vaccine strategy.
Researchers in South Africa are conducting a medical trial focused on controlling tuberculosis (TB) epidemics. The trial uses a novel approach that combines intensified household tracing and screening for TB and HIV using rapid molecular technologies.
Researchers at Osel have engineered Lactobacillus jensenii to stably express broadly neutralizing antibody fragments against the HIV-1 virus, offering a cost-effective and long-lasting new barrier to HIV-1 transmission. The engineered bacteria reduced vaginal HIV transmission in a primate animal model by over 63%.
According to a new study from Harvard T.H. Chan School of Public Health, Botswana has achieved remarkable progress in reducing the number of people who are infectious with HIV through strong treatment programs. The country has reported 96% viral suppression rates among patients on antiretroviral therapy, surpassing Western nations and ...
A recent study published in JAMA Pediatrics found that nearly 41% of young transgender women had one or more mental health or substance use disorders. The study also revealed a significant increase in depression, anxiety, and substance abuse among Latina young transgender women.
Scientists administered anti-HIV-1 human neutralizing monoclonal antibodies to infant rhesus macaques exposed to SHIV and found that the treatment completely cleared the virus within 14 days. This study shows that early administration of powerful antibodies can effectively clear a nonhuman primate virus similar to HIV.
A recent NIH study found that antibodies derived from unconventional B cells in HIV-infected individuals with uncontrolled virus levels are less effective at neutralizing HIV. The study suggests that the abnormal distribution of B cell types contributes to the lack of effective immune response.
A large clinical trial found that treating HIV patients at risk for tuberculosis with TB drugs does not save more lives. Simple TB screening and isoniazid preventive therapy were well-tolerated and resulted in similar survival rates compared to a four-drug TB treatment.
A survey of nearly 3,000 Ugandan students reveals that one in three had been in love with a person of the same sex and 6-8% of men engaged in homosexual relations. The study found associations between homosexual experiences and poor mental health, sexual coercion, and drug use.
A randomized clinical trial found that using four drugs for TB does not improve survival rates over isoniazid therapy in advanced HIV/AIDS patients. The study validates the World Health Organization guidelines for prescribing isoniazid to vulnerable patients.
The article discusses the nephrotoxic effects of newer antiviral therapies, such as HAART and DAAs, in HIV and HCV patients. Organic transporters play a crucial role in explaining potential renal toxicities, and a review highlights the substrates, inhibitors, and distribution of these transporters.
A new study published in The Lancet suggests that a low-cost, urine test to diagnose tuberculosis among patients with HIV could save thousands of lives per year in sub-Saharan Africa. The test, which provides results in 25 minutes and costs $2.66, showed an absolute reduction of 4% in TB death rate among patients with HIV.
Researchers found that a family-focused package of services can significantly reduce mother-to-child transmission of HIV in resource-limited areas. The study showed a 74% reduction in infant infections in the intervention group compared to the control group.
A study found that HIV patients in Africa with a certain genetic variant have a 63-percent lower chance of developing tuberculosis than those without the variant. This discovery may lead to the development of new TB treatments effective for both HIV-positive individuals and the general population.
A global study reveals 2.3 million people co-infected with HIV and hepatitis C, with a significant burden in Eastern Europe and central Asia. The study highlights the need for improved integrated HIV/HCV services and increased screening and treatment to reduce morbidity and new infections.
A new study by Harvard T.H. Chan School of Public Health finds that HIV/AIDS prevention and treatment will cost $261 billion if coverage is scaled up, exceeding domestic financing capabilities. The researchers emphasize the need for innovative funding sources to sustain control efforts.
Researchers have gained a clearer understanding of how HIV defeats a cellular defender by interacting with cyclophilin A. The study reveals that the virus uses cyclophilin A as a disguise to trick the cellular protein, allowing it to enter the nucleus and commandeer the cell.
A University of Cincinnati researcher is studying nearly 3,000 patients to see if a genetic variant that protects against HIV also prevents injury from Hepatitis C. The study aims to understand how inhibition of the CCR5 receptor may influence liver injury and disease progression in individuals co-infected with HIV and hepatitis C.
The study reveals the high-resolution structure of the HIV envelope protein, known as the Env trimer, in its natural form for the first time. The findings also include a detailed map of a vulnerable site at the base of this protein and the binding site of an antibody that can neutralize HIV.
A Harvard-Dartmouth study found that Zipf distributions of risk for diseases, such as HIV and heart attacks, lead pharmaceutical companies to invest more in treatments than preventives. This is because vaccine revenue depends on finer details about population risk, making it challenging to find a 'sweet spot' for pricing.
A study found that over 60% of newly diagnosed men in Rhode Island who have sex with men reported meeting sexual partners online. The researchers propose partnering with companies producing hookup websites and apps to share public health messages about the risks of sexual encounters arranged online.
Scientists have developed a new method to analyze the genetic tree of diseases like HIV to identify possible gaps in transmission chains. The study uses computational phylogenetic analysis to examine how strains of HIV are transmitted and can now evaluate the possibility of unsampled intermediaries or common sources.
A new study by San Diego State University found that Charlie Sheen's HIV-positive disclosure corresponded with record highs of domestic news coverage and Google searches for information about HIV and prevention. The study suggests that celebrity disclosures like Sheen's may help generate renewed national attention for HIV and HIV preve...
A Johns Hopkins study found record highs in domestic news coverage of HIV and Google searches for information about HIV and HIV prevention following Charlie Sheen's HIV-positive disclosure on NBC's TODAY Show. The study suggests that the public's response to Sheen's announcement led to an increase in people seeking out public health sa...
The dapivirine ring reduced the risk of HIV infection by 27 percent overall among more than 2,600 women in Africa. Women aged 25 and older saw a significant reduction in HIV risk, with some experiencing a cut in risk of over half.
Researchers at UC San Diego School of Medicine have discovered a crucial HIV RNA modification called m6A that influences viral replication. Silencing the enzyme adding or removing m6A from RNA can increase or decrease HIV replication, offering new avenues for developing effective anti-HIV therapies.
A study published in JAMA Internal Medicine found that Charlie Sheen's public disclosure of his HIV status led to a significant increase in Google searches related to the disease. The study suggests that this surge in interest may have benefited public health by raising awareness and driving people to learn more about HIV prevention.
Two large studies confirm the monthly vaginal ring's effectiveness in preventing HIV-1 infection in women, with a 30% overall reduction in infections. The ring's efficacy varies by age and consistent use, highlighting the need to overcome barriers to prevention for younger women.
Researchers at the University of Minnesota have made a breakthrough in understanding how retrovirus RSV brings together protein molecules to form tiny molecular claws, which can help develop anti-retrovirals to target integrase functions and improve HIV/AIDS therapies.
A special issue of the journal AIDS Research and Human Retroviruses highlights recent advances in HIV cure research, including studies on viral suppression and control of virus replication. Researchers discuss potential avenues for achieving a cure and propose exploring multiple approaches to therapy.
Researchers have determined the structure of a protein complex that lets viruses like HIV establish permanent infections in human cells. The new findings reveal a novel paradigm for retroviral DNA integration and provide insights into how viruses interact with host DNA.
A recent NYU study examined injection risk behaviors among heroin injectors in Colombian cities, finding 2.7% of participants tested positive for HIV and common practices like syringe sharing and clean needle exchange were prevalent. The study emphasizes the need for harm reduction interventions to prevent an HIV epidemic in Colombia.
A study published in Immunity found that innate lymphoid cells (ILCs) are destroyed in patients with acute HIV infection, highlighting the importance of early treatment. Research suggests that early intervention can protect ILCs from destruction and prevent immune system imbalances.
Dan R. Littman receives the $100,000 Vilcek Prize in Biomedical Science for his fundamental insights into the immune system and its role in HIV pathogenesis. Young researchers Fernando Camargo, Roberta Capp, and Houra Merrikh win $50,000 Vilcek Prizes for Creative Promise for their innovative work on blood cell development.
A study by University of Minnesota researchers identified the mechanism of 5-azacytidine, a DNA-based drug that blocks HIV's ability to spread. The drug converts to a DNA form and infiltrates HIV when it turns RNA into DNA, stopping replication.
Researchers found that HIV protein Tat alters networked neuron activity and leads to adaptations that improve survival but impair function. The study suggests that targeting these adaptations could facilitate therapeutic intervention for seizure disorders and other neurological symptoms in HIV-infected patients.
A large study found tenofovir-resistant strains in 60% of HIV patients in sub-Saharan Africa, highlighting a significant concern for global HIV control strategies. The study suggests that up to 15% of HIV patients will develop resistance in the first year of treatment alone.
Researchers found that HIV persists in lymphoid tissue despite potent antiretroviral therapy, and that low-level replication maintains viral reservoirs. The study provides a new perspective on how to deliver drugs to effectively eradicate the virus.
A new study funded by NIH suggests that ongoing HIV replication in lymphoid tissues maintains stores of the virus, a prerequisite for achieving a cure. Current ART regimens cannot eliminate persistent viral reservoirs, but sequencing data shows continued evolution over time without accumulating drug-resistant mutations.
Researchers deciphered how HIV's Tat protein interacts with host genes to activate or repress several hundred human genes. Blocking Tat activity may be therapeutic value for HIV patients, suggesting a promising approach to combat the deadly virus.
A randomized controlled trial evaluated consent for HIV testing, showing opt-out schemes can substantially increase patient acceptance compared to opt-in schemes. Active choice testing may be the most effective approach in reflecting patients' true preferences, researchers suggest.
Researchers identify SIM4, a new part of the TRIM5alpha protein that attaches to SUMO and activates an immune response against HIV. This finding could lead to optimizing gene therapy by tweaking the activity of antiviral factors.
A new study reveals significant racial disparities in treatment for patients with HIV and Hodgkin lymphoma, with black patients facing higher rates of non-treatment. Despite effective treatment options, doctors note that socioeconomic factors and lack of access to care may contribute to these disparities.
In a phase 1 trial, VRC01 antibody suppressed HIV levels by more than tenfold in six patients not on antiretroviral therapy, with some experiencing undetectable levels for up to 3 weeks. However, immune responses limited efficacy in others, highlighting the need for new strategies to prevent viral reservoirs.
A study published in The Lancet Global Health found that doctors trained on sexually transmitted infections (STIs) had 38% lower odds of patients being infected with gonorrhea or chlamydia. This training also led to improved knowledge among physicians and reduced rates of new STI transmissions.
A single infusion of VRC01 can suppress HIV levels by over 10-fold in some individuals, even without antiretroviral therapy. The treatment remains safe and well-tolerated, but its effectiveness varies depending on the individual's viral load.
Researchers found that South Africa reduced childhood deaths associated with HIV but failed to meet the MDG4 goal due to its narrow definition. The country's progress is deemed a 'success' when considering overall child mortality levels, despite not meeting the target.
A team of researchers at TSRI tracked the development of a family of antibodies that bind and neutralize HIV. By understanding how these antibodies evolve over time, scientists may be able to design a vaccine that triggers a faster immune response.
A study in rural Malawi found that antiretroviral therapy (ART) not only benefits HIV-positive individuals but also those without the disease. ART reduced perceived mortality risk and led to increased productivity among HIV-negative people, particularly in terms of corn production.
A new rapid test using polarized light can detect a wide range of pathogens, including malaria parasites, HIV, Ebola, diverse bacteria, glucose and cholesterol. The test is extremely fast, inexpensive, and flexible, making it suitable for use in areas with limited laboratory equipment.
A five-year, $60 million project will integrate HIV services with tuberculosis, malaria, family planning, nutrition, and other health services. The project aims to increase the availability, accessibility, and quality of health services for vulnerable populations in southwestern Uganda.
Research at Columbia University's Mailman School of Public Health found that young men with detectable HIV are more likely to engage in risky sexual behavior, particularly anal intercourse without condoms. This disproportionately affects vulnerable groups, such as those aged 13-29 and experiencing substance use issues.
Young men with HIV who have sex with men are more likely to report condomless anal sex, particularly with a partner not infected with HIV. Behavioral approaches to improve engagement in care and medication adherence may need to occur in concert with interventions to reduce risky sexual behaviors.
Scientists at Texas Biomed aim to develop a functional cure for babies born with HIV by testing a combination of antiviral drugs and vaccines in infant monkeys. The goal is to induce long-lasting protective immunity and eliminate the virus from tissue reservoirs.